Dan Teleman, CEO of Pharma Two B, added, “These data provide further support for P2B001 as a first-line, once-daily combination pill treatment for people with early PD that requires no titration.
Hepatitis B virus is a viral infection which affects the liver and can result in permanent liver damage. It is currently the leading cause of chronic liver | Immunology ...
We appreciate FDA’s support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long-term adverse outcomes of these desperately ill children.